| Literature DB >> 32984930 |
Rocco Maurizio Zagari1, Leonardo Henry Eusebi2, Giuseppe Galloro3, Stefano Rabitti2, Matteo Neri4, Luigi Pasquale5, Franco Bazzoli2.
Abstract
BACKGROUND: Little is known on practice patterns of endoscopists for the management of Barrett's esophagus (BE) over the last decade. AIMS: Our aim was to assess practice patterns of endoscopists for the diagnosis, surveillance and treatment of BE.Entities:
Keywords: Barrett’s esophagus; Diagnosis; Surveillance; Treatment
Mesh:
Year: 2020 PMID: 32984930 PMCID: PMC8379114 DOI: 10.1007/s10620-020-06615-6
Source DB: PubMed Journal: Dig Dis Sci ISSN: 0163-2116 Impact factor: 3.199
Demographic and professional characteristics of participants to the survey and members of the Italian Society of Digestive Endoscopy (SIED)
| Participants | Members of SIED | ||
|---|---|---|---|
| Sex | |||
| Male | 189 (73) | 572 (64.8) | |
| Female | 70 (27) | 311 (35.2) | 0.14 |
| Age group (years) | |||
| < 30 | 14 (5.4) | 33 (3.7) | |
| 30–40 | 71 (27.4) | 247 (28) | |
| 41–50 | 63 (24.3) | 180 (20.4) | |
| 51–60 | 82 (31.7) | 292 (33) | |
| > 60 | 29 (11.2) | 131 (14.8) | 0.30 |
| Area of residence | |||
| North-West | 72 (27.8) | 201 (22.8) | |
| North-East | 48 (18.5) | 162 (18.3) | |
| Center | 56 (21.6) | 204 (23.1) | |
| South and Islands | 83 (32) | 316 (35.8) | 0.37 |
| Practice setting | |||
| Community hospital | 178 (68.7) | 611 (69.2) | |
| University hospital | 61 (23.6) | 225 (25.5) | |
| Private hospital | 20 (7.7) | 47 (5.3) | 0.32 |
| Practice duration (years) | |||
| < 5 | 52 (20.1) | ||
| 5–10 | 37 (14.3) | ||
| 11–15 | 43 (16.6) | ||
| 16–20 | 36 (13.9) | ||
| > 20 | 91 (35.1) | ||
| Attendance to Barrett’s esophagus training course in the last 5 years | |||
| Yes | 158 (61) | ||
| No | 101 (39) | ||
Practice patterns of participants in the diagnosis of Barrett’s esophagus (BE)
| Participants | |
|---|---|
| I identify the gastro-esophageal junction with: | |
| Total | 255 |
| The top of gastric folds | 167 (65.5) |
| Distal end of the palisade vessels | 15 (5.9) |
| Z line | 69 (27) |
| Diaphragmatic hiatus | 4 (1.6) |
| The definition of BE is: | |
| Total | 256 |
| Columnar epithelium with intestinal metaplasia | 226 (88.3) |
| Columnar epithelium with or without intestinal metaplasia | 30 (11.7) |
| I describe the extension of BE using: | |
| Total | 258 |
| “Short” and “long” segment Barrett’s esophagus | 25 (9.7) |
| Barrett’s esophagus length only | 16 (6.2) |
| Prague C&M classification | 214 (82.9) |
| I do not describe Barrett’s esophagus extension | 3 (1.2) |
| In patients with areas of salmon-colored mucosa in the distal esophagus, I perform: | |
| Total | 256 |
| 1–2 random biopsies | 7 (2.7) |
| 3–4 random biopsies | 33 (12.9) |
| 4-quadrant biopsies every 1–2 cm | 216 (84.4) |
| I do not perform biopsies | 0 |
| In patients with BE, I use advanced endoscopic imaging techniquesa: | |
| Total | 255 |
| Routinely | 131 (51.4) |
| In case of suspected or known dysplasia/cancer | 75 (29.4) |
| Never | 49 (19.2) |
aHigh-definition endoscopy, Narrow Band Imaging, Autofluorescence imaging, Confocal laser endomicroscopy
Practice patterns of participants in the management of Barrett’s esophagus (BE)
| Participants | |
|---|---|
| My management of BE without dysplasia is: | |
| Total | 254 |
| Endoscopic surveillance in all patients | 142 (55.9) |
| Endoscopic surveillance with eradication treatment in selected casesa | 111 (43.7) |
| Endoscopic eradication treatment for all patients | 0 |
| Neither surveillance or endoscopic treatment | 1 (0.4) |
| I perform surveillance of BE without dysplasia: | |
| Total | 254 |
| Yearly | 17 (6.7) |
| Every 2 years | 59 (23.2) |
| Every 3 years | 157 (61.8) |
| Every 4 years | 2 (0.8) |
| Every 5 years | 17 (6.7) |
| > 5 years | 2 (0.8) |
| My management of BE with low-grade dysplasia is: | |
| Total | 254 |
| Endoscopic surveillance | 64 (25.2) |
| Endoscopic surveillance with eradication treatment in selected casesa | 137 (53.9) |
| Endoscopic treatment for all patients | 53 (20.9) |
| No surveillance or endoscopic treatment | 0 |
| I perform surveillance of BE with low-grade dysplasia: | |
| Total | 231 |
| Yearly | 196 (84.8) |
| Every 2 years | 23 (10) |
| Every 3 years | 11 (4.8) |
| Every 4 years | 0 |
| Every 5 years | 1 (0.4) |
| > 5 years | 0 |
| My management of BE with high-grade dysplasia or intramucosal carcinoma is: | |
| Total | 244 |
| Endoscopic treatment | 188 (77.1) |
| Referral to surgery | 40 (16.4) |
| Endoscopic surveillance with eradication treatment in selected casesa | 12 (4.9) |
| Endoscopic surveillance | 4 (1.6) |
| Which of the following endoscopic techniques do you use to eradicate BE: | |
| Total | 232 |
| I’m not able to perform any endoscopic eradication treatment | 186 (37.1) |
| I use at least one of the following techniquesb | 146 (62.9) |
| Endoscopic mucosal resection | 109 (46.7) |
| Radiofrequency ablation | 69 (29.7) |
| Argon plasma coagulation | 43 (18.5) |
| Endoscopic submucosal dissection | 29 (12.5) |
| Multipolar electrocoagulation | 6 (2.6) |
aAge < 40 years, BE length > 3 cm, family history for esophageal adenocarcinoma
bMore than one answer is allowed
Association between practice patterns of endoscopists and attendance to a training course on Barrett’s esophagus (BE) in the last 5 years
| Attendance to a training course on BE in the last 5 years | |||
|---|---|---|---|
| No | Yes | ||
| OR (95% CI) | |||
| Sex | |||
| Female | 37 (36.6) | 33 (20.9) | 1 |
| Male | 64 (63.4) | 125 (79.1) | 2.37 (1.16–4.82) |
| Age (years) | |||
| ≤ 50 | 58 (57.4) | 90 (57) | 1 |
| > 50 | 43 (42.6) | 68 (43) | 0.99 (0.46–2.15) |
| Practice setting | |||
| Community hospital | 71 (70.3) | 107 (67.7) | 1 |
| University hospital | 25 (26.7) | 36 (22.8) | 1.10 (0.49–2.29) |
| Private clinic | 5 (5) | 15 (9.5) | 1.75 (0.51–6.01) |
| Practice duration (years) | |||
| ≤ 10 | 38 (37.6) | 51 (32.3) | 1 |
| > 10 | 63 (62.4) | 107 (67.7) | 1.89 (0.87–4.09) |
| Use of Prague classificationa | |||
| No | 30 (30) | 14 (8.9) | 1 |
| Yes | 70 (70) | 144 (91.1) | 4.80 (1.9–12.1) |
| Use of the top of gastric folds as landmark for GEJb | |||
| No | 45 (45.9) | 43 (27.4) | 1 |
| Yes | 53 (54.1) | 114 (72.6) | 2.45 (1.27–4.74) |
| Use of Seattle biopsy protocolc | |||
| No | 13 (13.3) | 27 (17.1) | 1 |
| Yes | 85 (86.7) | 131 (82.9) | 0.43 (0.16–1.14) |
| Use of advanced endoscopic imaging techniquesb | |||
| No | 31 (31.3) | 18 (27.1) | 1 |
| Yes | 68 (68.7) | 138 (88.5) | 3.33 (1.53–7.29) |
| Endoscopic surveillance for non-dysplastic BE every 3–5 yearsd | |||
| No | 36 (36.4) | 42 (27.1) | 1 |
| Yes | 63 (63.6) | 113 (72.9) | 1.56 (0.79–3.09) |
| Use of endoscopic eradication techniquese | |||
| No | 33 (38.4) | 53 (36.3) | 1 |
| Yes | 53 (61.4) | 93 (63.7) | 0.76 (0.38–1.51) |
Advanced imaging endoscopy techniques: high-definition endoscopy, narrow band imaging, autofluorescence imaging or confocal laser endomicroscopy. Endoscopic techniques for BE eradication: endoscopic mucosal resection, endoscopic submucosal dissection, radiofrequency ablation, argon plasma coagulation or multipolar electrocoagulation
GEJ gastro-esophageal junction, OR odds ratio, CI confidence interval
aMissing data for one participant
bMissing data for four participants
cMissing for data for three participants
dMissing data for five participants
eMissing data for twenty-seven participants